56 Recruiting Studies Using Lenvatinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Lenvatinib
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
π University of California at San Francisco ( Site 1008) β San Francisco, California
Carcinoma, Renal Cell
View Study & Checklist βA Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
π Ironwood Cancer & Research Centers ( Site 0077) β Chandler, Arizona
Carcinoma, Renal Cell
View Study & Checklist βSubstudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
π University of California at San Francisco ( Site 3008) β San Francisco, California
Carcinoma, Renal Cell
View Study & Checklist βLenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
π M D Anderson Cancer Center β Houston, Texas
Metastatic Thyroid Gland Carcinoma
View Study & Checklist βA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
π The University of Alabama at Birmingham ( Site 0010) β Birmingham, Alabama
Carcinoma, Renal Cell
View Study & Checklist βLenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
π Stanford School of Medicine β Stanford, California
Renal Cell Carcinoma
View Study & Checklist βStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
π Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313 β Prescott Valley, Arizona
Hepatocellular Carcinoma
View Study & Checklist βLenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
π Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) β Basking Ridge, New Jersey
Advanced Sarcoma
View Study & Checklist βPembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
π M D Anderson Cancer Center β Houston, Texas
High Grade Fallopian Tube Serous Adenocarcinoma
View Study & Checklist βPembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
π University of Chicago Medicine β Chicago, Illinois
Ovarian Clear Cell Carcinoma
View Study & Checklist βA Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
π UAMS β Little Rock, Arkansas
Endometrial Neoplasms
View Study & Checklist βTesting Lenvatinib in Patients With Adenoid Cystic Carcinoma
π Memorial Sloan Kettering Cancer Center β Basking Ridge, New Jersey
Adenoid Cystic Carcinoma
View Study & Checklist βPerioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
π Emory University Hospital/Winship Cancer Institute β Atlanta, Georgia
Kidney Cancer
View Study & Checklist βA Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
π Medizinische UniversitΓ€t Innsbruck β Innsbruck,
Unresectable Hepatocellular Carcinoma
View Study & Checklist βLenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
π Ohio State University Comprehensive Cancer Center β Columbus, Ohio
Platinum-Resistant Fallopian Tube Carcinoma
View Study & Checklist βPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
π University of Arizona Cancer Center-University of Arizona Cancer Center - North Campus ( Site 5047) β Tucson, Arizona
Neoplasm Malignant
View Study & Checklist βLenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
π Moffitt Cancer Center β Tampa, Florida
Advanced Clear Cell Renal Cell Carcinoma
View Study & Checklist βPreoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
π University of Illinois β Chicago, Illinois
Triple Negative Breast Cancer
View Study & Checklist βPembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
π City of Hope β Duarte, California
Prostate Cancer Metastatic
View Study & Checklist βNeoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
π Moffitt Cancer Center β Tampa, Florida
Merkel Cell Carcinoma
View Study & Checklist βLenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
π Baptist Alliance MCI β Miami, Florida
Adenoid Cystic Carcinoma
View Study & Checklist βStudy of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
π Research Site β Birmingham, Alabama
Hepatocellular Carcinoma
View Study & Checklist βLenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
π City of Hope Medical Center β Duarte, California
Advanced Pancreatic Ductal Adenocarcinoma
View Study & Checklist βLenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
π M D Anderson Cancer Center β Houston, Texas
Advanced Carcinoid Tumor
View Study & Checklist βChemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
π City of Hope Medical Center β Duarte, California
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
View Study & Checklist βA Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
π Research Site β Washington D.C., District of Columbia
Advanced Renal Cell Carcinoma
View Study & Checklist βEvaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
π Research Site β Birmingham, Alabama
Hepatocellular Carcinoma
View Study & Checklist βA Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
π Memorial Sloan Kettering Basking Ridge (Limited protocol activities) β Basking Ridge, New Jersey
Uterine Carcinosarcoma
View Study & Checklist βSafety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
π Banner MD Anderson Cancer Center ( Site 0152) β Gilbert, Arizona
Small Cell Lung Carcinoma
View Study & Checklist βPembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
π M D Anderson Cancer Center β Houston, Texas
Advanced Gastric Adenocarcinoma
View Study & Checklist βA Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
π M D Anderson Cancer Center β Houston, Texas
Tumor
View Study & Checklist βMerck IIT: RRP Pembro and Lenvatinib
π Yale University β New Haven, Connecticut
Human Papilloma Virus
View Study & Checklist βPhase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
π M D Anderson Cancer Center β Houston, Texas
Brain Metastases
View Study & Checklist βLenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
π University of California, San Francisco β San Francisco, California
Neuroendocrine Tumors
View Study & Checklist βA Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
π Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) β Basking Ridge, New Jersey
Metastatic Breast Cancer
View Study & Checklist βNeoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
π Abramson Cancer Center at University of Pennsylvania β Philadelphia, Pennsylvania
Renal Cell Carcinoma
View Study & Checklist βA Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
π City of Hope β Duarte, California
Advanced Hepatocellular Carcinoma
View Study & Checklist βA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
π University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) β Tucson, Arizona
Esophageal Squamous Cell Carcinoma
View Study & Checklist βGI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
π Tisch Cancer Institute (TCI), Icahn School of Medicine β New York, New York
Advanced Solid Tumor
View Study & Checklist βExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
π Beth Israel Deaconess Medical Center ( Site 0107) β Boston, Massachusetts
Von Hippel-Lindau Disease
View Study & Checklist βPembrolizumab and Lenvatinib in Advanced Cervical Cancer
π MedStar Georgetown University Hospital β Washington D.C., District of Columbia
Cervical Cancer
View Study & Checklist βA Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRΞ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
π ACRC/Arizona Clinical Research Center, Inc β Tucson, Arizona
Solid Tumor
View Study & Checklist βPembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
π National Institutes of Health Clinical Center β Bethesda, Maryland
Endometrial Cancer
View Study & Checklist βLenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
π University of Chicago Medicine Comprehensive Cancer Center β Chicago, Illinois
Carcinoma, Squamous Cell
View Study & Checklist βVisugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
π USC Norris Comprehensive Cancer Center β Los Angeles, California
Unresectable or Metastatic Hepatocellular Carcinoma
View Study & Checklist βPhase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
π University of Miami β Miami, Florida
Recurrent Endometrial Carcinoma
View Study & Checklist βAtezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
π Mayo Clinic in Arizona β Scottsdale, Arizona
Locally Advanced Hepatocellular Carcinoma
View Study & Checklist βCB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
π Dana Farber Cancer Institute β Boston, Massachusetts
Adenoid Cystic Carcinoma
View Study & Checklist βA Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
π City of Hope National Medical Center /ID# 270526 β Duarte, California
Hepatocellular Cancer
View Study & Checklist βAdding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
π Highlands Oncology Group - Fayetteville β Fayetteville, Arkansas
Advanced Clear Cell Renal Cell Carcinoma
View Study & Checklist βPembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy
π University of Miami β Miami, Florida
Recurrent Endometrial Cancer
View Study & Checklist βStudy of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
π UT Southwestern Medical Center β Dallas, Texas
Cervix Cancer
View Study & Checklist βLenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
π Washington University School of Medicine β St Louis, Missouri
Thyroid Cancer
View Study & Checklist βTesting the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Metastatic Renal Cell Carcinoma
View Study & Checklist βSTRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
π Arthur J.E. Child Comprehensive Cancer Centre β Calgary, Alberta
Hepatocellular Carcinoma
View Study & Checklist βLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
π Arizona Cancer Center at UMC North ( Site 0018) β Tucson, Arizona
Solid Tumors
View Study & Checklist β